Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCP-001 vaccination regimens in AML remission with persistent MRD
NL-OMON52641Phase 2Completed
- Sponsor
- Mendus
- Start
- Nov 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vididencel in acute myeloid leukemia (AML) (2 arms), sponsored by Mendus. Primary endpoints: Change in minimal residual disease, Change in immunoreactivity and 1 more. Started Nov 2018; status: completed.
02
Drugs
vididencel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON52641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52641.